Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. AnazaoHealth Corporation
483
•AnazaoHealth Corporation•August 8, 2025

AnazaoHealth Corporation – FDA 483, Aug 8, 2025

Record Details

**FDA 483 Summary for AnazaoHealth Corporation**

**Inspection Dates:** July 28, 2025, to August 8, 2025 **Location:** Las Vegas, NV **Facility Type:** Outsourcing Facility **Individual Addressed:** Douglas F. Cammann, Vice President of Operations

**Key Observations and Issues:**

1. **Production and Process Controls:** AnazaoHealth failed to establish adequate written procedures to ensure drug products meet identity, strength, purity, and quality standards. Specifically, the firm did not assess pellet-to-pellet content uniformity and did not validate compression speed as a controlled parameter, leading to potential quality inconsistencies.

2. **Microbiological Contamination Prevention:** The firm lacked proper procedures to prevent contamination in sterile drug products. Observations included exposure of sterile packaging to non-sterile environments and inadequate validation of hold times for depyrogenized equipment, risking sterility and product integrity.

3. **Complaint Handling:** The firm"s complaint investigations were inadequate, lacking retain sample testing for quality-related adverse events. This deficiency was noted in cases involving testosterone pellets and Ascorbic Acid, where potential sterility and quality issues were not thoroughly evaluated.

4. **Laboratory Records:** Laboratory records were incomplete, failing to include necessary data for compliance assurance. The firm did not test individual pellets for content uniformity or perform hardness testing, compromising the assurance of product consistency and quality.

**Regulatory Framework:** These observations are reported under the FD&C Act Section 704(b) to assist AnazaoHealth in achieving compliance.

**Required Actions:** AnazaoHealth must address these deficiencies by implementing corrective actions, including establishing robust process controls, enhancing contamination prevention measures, improving complaint investigation procedures, and ensuring comprehensive laboratory testing and documentation.

Company
AnazaoHealth Corporation
Inspection date
August 8, 2025
Product type
Drugs
Office
Los Angeles District Office
People
  • Douglas I. Ellsworth (President)
  • Taichun Qin (Consumer Safety Officer, Drug Specialist)
  • Tonia F (Investigator)
View Company Profile

ID · 898fc70d-779a-49c3-852a-987b7e63ec28

Other documents for AnazaoHealth Corporation
  • 483 - 2024-09-23September 23, 2024
  • 483 - 2022-07-29July 29, 2022
  • 483 - 2019-09-19September 19, 2019
  • WARNING_LETTER - 2019-09-19September 19, 2019
  • 483 - 2017-03-24March 24, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AnazaoHealth Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.